NCT01506427

A Study of [F-18]HX4 (PET Imaging)Evaluated in Head and Neck Cancer Patients

A Phase I/II, Open Label, Nonrandomized, Multi-Center Study of [F-18]HX4 Positron Emission Tomography (PET) in Head and Neck Cancer Patients

• Status: Withdrawn
• Phase: Phase 1 / Phase 2
• Study type: Interventional
• Enrollment: 0 (actual)
• Sponsor: Siemens Molecular Imaging · Industry
• Sex: All
• Age: —
• Healthy volunteers: Not accepted

Summary

The purpose of this trial is to determine what will be the optimal imaging protocol for Head and Neck Cancer patients after \[F-18\] HX4 injection. This study will provide guidance for future studies involving \[F-18\]HX4 in cancer patients.

Detailed description

Each consented patient will have a single administration of \[F-18\]HX4 and will immediately undergo one list mode PET/CT imaging session lasting 60 minutes followed by three additional list mode PET/CT acquisitions from 90 to 110 minutes, 150 to 170 minutes and 220 to 250 minutes after administration. The start times of the last three image acquisitions are permitted to be within ± 5 minutes. Venous blood samples will be collected throughout the initial scan sequence and at the time of each subsequent acquisition for calibration and metabolite-correction of the image-derived input function. On the day of administration (Visit 2) blood for clinical safety evaluations will be drawn pre- and post-dosing after all imaging is complete. The pre-surgery \[F-18\]FDG PET/CT clinical scan performed prior to the \[F-18\]HX4 procedure, and the surgery at Visit 3 are standard of care for the consented patients.

Conditions

• Head and Neck Cancer

Interventions

Type	Name	Description
RADIATION	[F-18] HX4	A single dose of 10 mCi, injected intravenously.

Timeline

• Start date: 2012-09-01
• Primary completion: 2013-04-01
• Completion: 2013-06-01
• First posted: 2012-01-10
• Last updated: 2012-12-17

Locations

1 site across 1 country: United States